Novo Nordisk's GLP-1 Fortress Shows Cracks as Rivals Close In From Every Side

Novo Nordisk shares fall 11% YTD as Eli Lilly's oral GLP-1 launch and generic threats erode its weight-loss edge, despite guidance raise.

The competitive moat around Novo Nordisk's weight-loss franchise is thinning from multiple directions at once, and the Danish drugmaker's share price is quietly reflecting the strain.

The stock closed Monday at EUR 39.10, down 0.8 percent on the day, with losses now stretching to 6.0 percent over the past seven trading sessions. Since the start of the year, the shares have shed 11 percent, leaving them 29 percent below the 52-week high of EUR 54.86 touched in late January. The relative strength index sits at 41.9 — not yet oversold, but pointing to a market that has lost confidence in the near-term story.

The Oral Race Is Slipping Away

The most pressing concern centers on oral GLP-1 treatments, where Eli Lilly has stolen a march on its Danish rival. Lilly launched its oral weight-loss drug Foundayo in Britain in mid-August, just days after receiving approval from UK regulators on August 10. Reuters characterized the move as a direct competitive strike against Novo Nordisk's Wegovy pill, which had previously enjoyed the distinction of being the first oral GLP-1 therapy available in the UK market.

That first-mover advantage has now evaporated, and the symbolism matters as much as the immediate commercial impact. Novo Nordisk built its empire on being early — losing that edge in a key market segment raises uncomfortable questions about whether the company can maintain its leadership position as the therapeutic category matures.

Generic Pressure From an Unlikely Corner

Adding to the squeeze, Polish drugmaker Celon Pharma reported that its experimental semaglutide product, Reduzek, matched the efficacy of Wegovy and Ozempic in an early bioequivalence study. The candidate is being developed as a generic alternative, and while the data comes from a preliminary phase, the implications are significant: if copycat products can achieve parity with the originals this early in the development cycle, the economic value of Novo Nordisk's patent protection may erode faster than the current share price suggests.

The company is also dealing with a self-inflicted wound. Scholar Rock was forced to withdraw its European marketing application for a spinal muscular atrophy treatment after problems emerged at a manufacturing facility owned by Novo Nordisk. Quality issues in the company's own production network are not a sideshow — they cut to the heart of the trust relationship with regulators and partners.

Washington's Price Push Fades Into the Background

On the political front, the Trump administration on Monday announced voluntary pricing agreements with nine additional pharmaceutical companies — Alcon, Astellas, BeOne, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB — expanding the program launched in January 2025 to 26 companies representing roughly 90 percent of the US pharmaceutical market.

Novo Nordisk was already part of an earlier round of these deals, so the latest expansion brings no new obligations. The arrangement follows a familiar template: companies grant Medicaid most-favored-nation pricing on chronic and rare disease treatments, aligning US list prices with international levels, in exchange for tariff relief or exemptions from planned Medicare pilot programs. A 2024 Rand Corporation analysis found US prescription drug prices average nearly three times those in 33 other countries.

The administration claims savings of several hundred billion dollars over a decade through these agreements and initiatives like the TrumpRx platform — a figure independent experts have pushed back on, noting that price pressure from GLP-1 therapies and generic competition has played a larger role. Historically, Novo Nordisk's shares have reacted mildly negatively to such announcements, with the heaviest selling reserved for companies left out of the deals entirely. Since Novo is already inside the tent, the political variable appears to be losing its relevance for the stock — competitive dynamics in the weight-loss market have become the decisive factor.

A Pipeline That Works — But Slowly

There are bright spots. The company raised its full-year sales and profit guidance, now projecting zero to minus 6 percent growth versus 2025, an improvement from the previous range of minus 12 to minus 4 percent. The late-stage OASIS-5 study, launched August 12, will test lower maintenance doses of the Wegovy pill over 60 weeks, with results expected by 2028. Research with Novonesis on microbiome-based supplements to complement GLP-1 therapies won't deliver data until the second half of 2027.

Those timelines are the problem in miniature. Management points to a vast untapped market — CEO Mike Doustdar notes that over 100 million Americans are obese, with only a fraction currently accessing GLP-1 medications — but the growth narrative now hinges on horizons that stretch well beyond the current market cycle. By the time those studies read out, Eli Lilly and a wave of generic challengers will have had years to consolidate their positions.

The stock trades near its 100-day average of EUR 39.47 and roughly 29 percent above its 52-week low of EUR 30.25, having clawed back some ground from the worst levels. Yet the RSI of 41.4 and a 6.7 percent gap below the 50-day average suggest the market remains unconvinced by the recovery story.

The third-quarter results, due November 4, will provide the first real opportunity to assess how intensifying competition is translating into revenue and margin pressure. Until then, the shares look caught between a stabilizing operational picture and a competitive landscape that is shifting faster than the company's pipeline can respond. The operational improvement is real — but so is the strategic challenge, and for now the latter carries more weight.